Metabonomic Profiling: A Novel Approach in Neuroendocrine Neoplasias Abstract #965

Introduction: There is a substantial unmet need for novel biomarkers for neuroendocrine neoplasms (NEN).
Aim(s): An analytical platform was developed to define a diagnostic metabolic phenotype for NEN.
Materials and methods: Forty-nine patients with NEN were prospectively recruited: 15 small bowel NEN [SBNEN]; 21 pancreatic NEN [PNEN], 13 other NEN. There were 21 healthy controls. Urine samples were subjected to 1H nuclear magnetic resonance spectroscopy on a Bruker Avance III 600 MHz spectrometer. Acquired spectral data were imported into SIMCA-P for supervised and unsupervised multivariate analysis. Selected samples were used for two-dimensional nuclear magnetic resonance spectroscopy (2D-NMR) for metabolite identification in an 800 MHz Bruker Avance II spectrometer.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Professor Beatriz Jiminez
Keywords: Metabonomics, NEN

To read results and conclusion, please login ...

Further abstracts you may be interested in

#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Rocio Garcia Carbonero
#2209 The ENETS Registry: First Results of a Collaborative Effort Including over 12.000 Patients with Neuroendocrine Neoplasms (NENs) from 7 European Countries
Introduction: NENs are rare and global European epidemiologic data are only based on national or compilation of national registries. So, there is a need for comprehensive homogenous information
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni